InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,156.81
(
0.57%
)
US TECH 100
17,522.00
(
0.59%
)
Dow Jones
38,805.53
(
0.34%
)
Brent Oil
83.43
(
0.37%
)
Bitcoin
64,030.21
(
0.05%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 198102

Wednesday, 12/09/2015 7:52:44 PM

Wednesday, December 09, 2015 7:52:44 PM

Post# of 251721
CHRS -14% on required re-do of Neulasta-FoB bioequivalence study (#msg-119019743).

In contrast to CHRS’ +10% move on Oct 2—which showed profound misunderstanding by investors of the 351(k) regulatory pathway (#msg-117437374)—today’s 14% drop seems about right.

CHRS’ management lost a lot of credibility with the heavy BS in yesterday's PR and the way they handled this incident in general.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up